Walgreens and Labcorp make Pixel by Labcorp At-Home COVID-19 Collection Kit available
Labcorp and Walgreens announced that the Pixel by Labcorp At-Home COVID-19 Collection Kit is now available from Labcorp through Walgreens Find Care, a digital health platform available on the Walgreens app and Walgreens.com.
Walgreens currently offers COVID-19 testing in more than 1,100 drive-thru locations across the country. Using Walgreens Find Care, customers can connect to the Pixel by Labcorp website to request the test after completing a short COVID-19 survey to determine eligibility. The kit will be shipped via FedEx Express Overnight to the customer’s home, where they can self-administer the test collection using a short nasal swab and send their sample back to Labcorp. Once processed by Labcorp, test results are accessed by the customer via the Pixel by Labcorp site. If a COVID-19 test is positive, a healthcare staff member will contact individuals directly by phone or mail to discuss next steps.
Pixel by Labcorp has contracted with a physician network to provide independent physician services for testing. The Pixel by Labcorp At-Home COVID-19 Collection Kit is not a substitute for visits to a healthcare professional and is for use by adults 18 and older.
Currently through Walgreens Find Care, patients can access more than 40 providers that together offer more than 60 services and treat more than 100 conditions. The launch of additional features and providers on Walgreens Find Care coincided with guidance from the Centers for Disease Control and Prevention (CDC) to use telehealth to help address medical needs while supporting social distancing, an important step in managing the impact of COVID-19.
Labcorp’s COVID-19 PCR test has not been U.S. Food and Drug Administration (FDA) cleared or approved and has been authorized by the FDA under an emergency use authorization only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
